Portola Pharmaceuticals (PTLA) said on Monday a new analysis from its phase 3b/4 trial of Andexxa continued to show its ability to stop hemorrhage in patients with acute gastrointestinal bleeding while taking blood thinner drugs. The stock gained over 2% in late trade.

“This ANNEXA-4 sub-analysis of patients with bleeding in the GI tract — the most common site of anticoagulant-related bleeding — continues to demonstrate the consistency of the hemostatic efficacy and safety of Andexxa,” Deborah Siegal, assistant professor at McMaster University in Hamilton, Ontario, said in a statement.